The backlash over high drug prices is hitting pharma where it hurts
"The simmering public outrage over drug prices finally seems to be catching up to the pharmaceutical industry. Earnings reports in recent days have laid out a grim picture of slumping sales and anemic growth projections at several large drug makers and wholesalers. Executives blame many factors — including heavy competition and hardball tactics from insurers — but analysts say the bottom line is crystal clear: Pharma can no longer count on steadily hiking drug prices."
Click below to read more.